Stock Watch: Cancer Combination Therapies Face Rising Bar
Additive Improvements Are Getting Harder To Demonstrate
Executive Summary
Improving efficacy by combining drugs has been a mainstay of cancer therapy but adding new targeted drugs together based on very early-stage data is not working out, especially when one of the drugs is barely active on its own.
You may also be interested in...
GSK Files Its BCMA Drug In Multiple Myeloma
GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate of 31% in patients with heavily pre-treated multiple myeloma.
Stock Watch: Orphan Drug Profitability Under Threat
The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?
Stock Watch: Pfizer Gets Back To Business As Usual
Sales Of Pfizer’s pandemic products decline as other vaccines are scheduled for a second-half launch but the road back to 2022’s all-time high in annual revenues will not be easy.